Clinical Characteristics and Risk Factors of Hypersensitivity Reactions to Iron Isomaltoside in Gynaecological Patients with Iron Deficiency Anaemia: A Retrospective Pharmacovigilance Study
This retrospective pharmacovigilance study of 611 Chinese gynaecological patients identifies concomitant intravenous antibiotic use, elevated baseline platelet count, and reduced pre-infusion haemoglobin as independent risk factors for hypersensitivity reactions to iron isomaltoside, which predominantly occur within the first 30 minutes of infusion.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the world of modern medicine, iron is a vital mineral that carries oxygen through the blood, and when levels drop too low, patients suffer from iron deficiency anemia. For decades, doctors have treated this condition with intravenous iron infusions, but early versions of these medicines were unstable and carried a high risk of dangerous reactions. Over time, scientists developed newer, safer generations of iron drugs. One of the most advanced is a substance called iron isomaltoside, which allows doctors to deliver a large dose of iron quickly in a single session without the patient needing to return for multiple treatments. While this drug has become a standard tool for treating anemia in women with gynecological conditions like heavy bleeding or tumors, it is not without risk. Like many potent medications, it can occasionally trigger the body's immune system to overreact, causing what doctors call hypersensitivity reactions. These events can range from mild skin rashes to serious breathing difficulties, and while they are known to happen, doctors have lacked a clear picture of how often they occur in Chinese hospitals or exactly which patients are most likely to experience them.
To fill this gap in knowledge, a team of researchers at The First Affiliated Hospital of Xiamen University conducted a careful review of real-world medical records. They focused on women who were hospitalized for gynecological issues and received iron isomaltoside infusions between July 2024 and December 2025. The team used a sophisticated hospital safety system that automatically scans patient records for specific warning signs, such as mentions of chest tightness, skin itching, or breathing trouble that occur during or shortly after the infusion. When the system flagged a potential reaction, two qualified clinical pharmacists manually reviewed the case to confirm if the drug was truly the cause. They compared the 27 women who had confirmed reactions against a group of 108 women who received the same treatment but had no adverse effects, matching them closely by age, body size, and the specific gynecological condition they were being treated for. This method allowed the researchers to isolate the factors that truly made a difference, rather than just looking at general trends.
The study revealed that hypersensitivity reactions to this iron drug are not rare, occurring in about 4.4 percent of the patients treated. Most importantly, the researchers found that these reactions happen very quickly. On average, symptoms began just over 25 minutes after the infusion started, and nearly three-quarters of all reactions appeared within the first 30 minutes. The most common signs were skin-related, such as flushing or itching, followed by respiratory issues like chest tightness or shortness of breath. Fortunately, every patient in the study recovered fully after doctors paused the infusion and provided supportive care, such as oxygen or medication to calm the reaction. In some cases, the infusion had to be stopped permanently, but for most, the treatment could be resumed safely once the symptoms subsided.
Perhaps the most significant finding was the identification of three specific factors that independently increased a patient's risk of having a reaction. The first factor was the use of intravenous antibiotics at the same time as the iron infusion. Patients who received antibiotics within 24 hours before the iron treatment were significantly more likely to react. The second factor was the patient's baseline platelet count, a measure of how many blood cells are available to help clot wounds; higher-than-normal platelet counts were linked to a higher risk. The third factor was the level of hemoglobin, the protein that carries oxygen in the blood. Patients who started with lower hemoglobin levels were at greater risk. The study explicitly found that other common variables, such as the total dose of iron given, the time between mixing the drug and giving it, or a history of drug allergies, did not predict who would have a reaction.
These results suggest that the risk of a reaction is not random but is tied to specific, measurable conditions in the patient's body and their concurrent treatments. The researchers propose that the combination of iron nanoparticles and certain antibiotics might trigger a stronger immune response in some individuals, while the presence of high platelet counts and low hemoglobin may signal an underlying state of inflammation that makes the body more sensitive. The study concludes that doctors can improve safety by being extra vigilant with patients who fit these profiles. By checking for these specific risk factors before starting the infusion and monitoring vital signs closely during the first half-hour of treatment, medical teams can catch reactions early and manage them effectively. This work provides a clear, data-driven guide for using a powerful medicine more safely, ensuring that the benefits of rapid iron replacement are not overshadowed by preventable risks.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.